A B S T R A C T We have examined the basis for the recently reported, but unexplained deficiency of Sadenosylhomocysteine hydrolase (AdoHcyase) in the erythrocytes of patients with genetic deficiencies of purine nucleoside phosphorylase and hypoxanthineguanine phosphoribosyltransferase. We found that a hemolysate from a patient with purine nucleoside phosphorylase deficiency had only 7% of control Ado-Hcyase activity, confirming the original observation. Of the purine nucleosides known to accumulate in nucleoside phosphorylase-deficient patients, inosine alone caused the phosphate-dependent, irreversible inactivation of purified huiman placental AdoHcyase, and of AdoHcyase in intact erythrocytes and cultured lymphoblastoid cells. Hypoxanthine did not inactivate purified AdoHcyase, but potentiated the effect of inosine in intact hypoxanthine-guanine phosphoribosyltransferase-deficient human lymphoblastoid cells. This presumably resulted from the ability ofhypoxanthine to shift the equilibrium of the nucleoside phosphorylase reaction, preventing inosine breakdown. This could account for the partial AdoHcyase deficiency reported in hypoxanthine-guanine phosphoribosyltransferasedeficient patients. We have also demonstrated the AdoHcyase-catalyzed synthesis of S-inosylhomocysteine from inosine and L-homocysteine, a reaction which may occur in nucleoside phosphorylasedeficient patients.
INTRODUCTION
Adenosine deaminase (ADA),' purine nucleoside phosphorylase (PNP) , and hypoxanthine-guanine phos-phoribosyltransferase (HGPRT) catalyze sequential steps in the interconversion of purine nucleosides and reutilization of purine bases. Their respective deficiencies cause a severe combined immunodeficiency disease (ADA) (1), a selective defect in cell-mediated immunity (PNP) (2) , and the Lesch-Nyhan syndrome (HGPRT) (3, 4) , in which marked urate overproduction is accompanied by a severe neurologic disease. Recent evidence has suggested some involvement of the enzyme S -adenosylhomocysteine hydrolase (AdoHcyase) in each of these inborn errors of purine metabolism.
AdoHcyase catalyzes the reversible cleavage of S-adenosylhomocysteine (AdoHcy) to adenosine and L-homocysteine (5), a reaction which is essential to prevent the accumulation of AdoHcy, both a product and a potent inhibitor of S -adenosylmethionine-dependent transmethylation reactions. We have identified Ado-Hcyase as the major high affinity adenosine-binding protein in the cytoplasm (6) , and have shown that it may mediate toxic effects ofboth adenosine and deoxyadenosine, the nucleosides which accumulate in ADA deficiency. Adenosine, by displacing the equilibrium of the AdoHcyase reaction, causes AdoHcy accumulation and inhibition of nucleic acid methylation in ADA-inhibited cultured lymphoid cells (7, 8) . Deoxyadenosine (and the antiviral agent adenine arabinoside) causes the irreversible inactivation of AdoHcyase (9) , such that erythrocytes of ADA-deficient children have <2% of normal AdoHcyase activity (10) . In cultured human lymphoblastoid cells, this inactivation causes AdoHcy accumulation and contributes to the toxicity of deoxyadenosine (11) . These mechanisms may contribute to S-adenosylhomocysteine hydrolase; Ara-A, adenine arabinoside; Ara-Hx, arabinosylhypoxanthine; HGPRT, hypoxanthine-guanine phosphoribosyltransferase; InoHcy, S-inosylhomocysteine; PNP, purine nucleoside phosphorylase. the lymphopenia and immune dysfunction in ADA deficiency.
Recently, Kaminska and Fox (12) reported that PNPdeficient patients had 12-19% of normal erythrocyte AdoHcyase activity, and Lesch-Nyhan patients, 50-60%, though the researchers were unable to define the cause of this deficiency. They reported that none of the purines that accumulate in PNP-and HGPRTdeficient patients affected AdoHcyase activity, and suggested that their AdoHcyase deficiency might result from some mechanism other than the type of inactivation caused by deoxyadenosine. We have reexamined this question, both because of our interest in the unusual properties of AdoHcyase and because understanding the cause of its deficiency is necessary to assess its possible role in prodtucing the immunologic or neurologic abnormalities in these patients.
METHODS
Materials. Radioactive chemicals were obtained from Amersham Corp., Arlington Heights, Ill.; nonradioactive compounds from Sigma Chemical Co., St. Louis, Mo., or P-L Biochemicals, Inc., Milwaukee, Wise.; cellulose thin-layer plates from Eastman Kodak, Rochester, N. Y. The nonspecific ADA from Aspergillus oryzeae was purified (13) from Sanzyme-R (Calbiochem-Behring Corp., American Hoechst Corp., San Diego, Calif.), and was a gift from Dr. N. Kredich.
AdoHcyase was puirified from human placenta by a procedure to be described in detail elsewhere.2 The enzyme was homogeneous by the criteria of sodium dodecylsulfateacrylamide gel electrophoresis and analytical ultracentrifugation, and contained 1 mol tightly bound NAD+/mol of subunit (48,000 mol wt), as described for beef liver Ado-Hcyase (14) .
Cell growth an(l preparation of extracts. Clone 35-1, an HGPRT-deficient mutant (15) of the WI-L2 human splenic lymphoblastoid cell line, was grown as described (16) , except that 10o horse serum was tused instead of fetal calf serum.
For measuring AdoHcyase in extracts, the cells were harvested by brief centrifugation at 4°C, and washed once with phosphate-btuffered NaCl; the cell pellet was frozen and thawed three times in 0.1 ml of Tris-HCl, pH 7.4, 1 mM Na2EDTA. After centriftugation for 2 min in a Beckman microfuge (Beckman Instruiments Inc., Ftullerton, Calif), 0.1 ml of stupernate was passed over Sephadex G-25 as described (11) . Hemolysates prepared as described (10) were treated similarly, and the excltuded fractionis from the G-25 columns were assayed for AdoHcyase.
Assays. AdoHcyase was assayed in the direction of AdoHcy synthesis from ['4C]adenosiine and L-homocysteine, using a thin-layer chromatographic method (6, 9) . In the assay of S-inosylhomocysteine (InoHcy) synthesis by purified placental AdoHcyase, [8-'4C]inosine ( oryzeae ADA) was tused as ai thin-layer mlarker instead of AdoHcy. The prodict ofthe reactioni was also shown to coeltute with InoHcy by high-press;ure liquidi chromntatography on a C,8 uBondapak reversed-phase column (Waters Associates, Inc., Milford, Mass.), eltuted with 50 mM soditum acetate, pH 3.9, 2 Hershfield, M. S., and W. C. Smiall. Mantuscript in preparation. 
RESULTS
A hemolysate from a PNP-deficient patient was kindly provided to us by Dr. S. K. Wadman, Utrecht Universiteitskinderklineik, Utrecht, The Netherlands. It had normal levels ofADA and adenine phosphoribosyltransferase activities, but its AdoHcyase activity, 0.27 nmol/h/mg protein, was only 6-7% of our control population erythrocyte activity (10) . This confirmed the result reported by Kaminska and Fox (12), who found values of -15% of controls. In studying possible explanations for this deficiency, they evaluated the effects of inosine, deoxyinosine, guanosine, deoxyguanosine (PNP substrates), and of hypoxanthine and guanine (PNP products, HGPRT substrates) on AdoHcyase activity in hemolysates of normal individuals. To prevent breakdown of the nucleosides by PNP present in these hemolysates, they chose to conduct these studies in phosphate-free buffer. Under these assay conditions, they found no effect ofany ofthe above mentioned compouinds (0.5 mM, 20-and 60-min incubations) on Ado-Hcyase, but did observe inactivation by deoxyadenosine, used as a "positive control." In our published studies of AdoHcyase inactivation we have used phosphate-containing buffers (9) (10) (11) . Furthermore, we have found that the rate of inactivation of homogeneous placental AdoHcyase by several purines is phosphate dependent (17) . Fig. 1 compares the rates of inactivation of homogeneous human placental AdoHcyase, in the presence and absence of 10 mM phosphate, by 0.05 mM adenine arabinoside (Ara-A), 0.2 mM arabinosylhypoxanthine (Ara-Hx), and by 0.2 mM inosine, demonstrating the phosphate dependence of the rates of inactivation by Ara-A and inosine. No inactivation was observed with 0.2 mM inosine in the absence of phosphate, and Ara-Hx did not inactivate even in the presence ofphosphate. In similar kinetic experiments performed in the presence ofphosphate, we observed no appreciable inactivation with 0.25 mM hypoxanthine, guanine, deoxyinosine, guanosine, or deoxyguianosine (Table I ). The rate of inactivation by inosine is pseudo-first order and saturable (Fig. 2) . From these studies we determined a K, (18) for inosine as an inactivator of 5.85 mM, with a Vmax of 0.16 min-'. In experiments not shown, we also found that prolonged dialysis (up to 68 h) did not restore activity to inosine-treated AdoHcyase (dialyzed, untreated enzyme lost no activity), and that low concentrations of adenosine blocked inactivation of the enzyme by inosine. Thus the inactivation by inosine is irreversible and is active site directed, as we previously showed with deoxyadenosine and adenine arabinoside Triangles, Ara-Hx, 0.2 mM; circles, inosine, 0.2 mM; squiares, Ara-A, 0.05 mM. (9) . We have also found that inosine can replace adenosine as a substrate for human AdoHcyase, combining with L-homocysteine to form inosylhomocysteine (InoHcy) (Fig. 3 ). However, this is a very inefficient reaction, with a Km of 9.3 mM, compared with a Km for adenosine of 1 ,uM (6) . More detailed studies of the mechanism of inactivation by inosine and effects of InoHcy on cells will be presented elsewhere.
In other experiments (not shown), we found that exposure to 0.25 mM inosine for 2 h caused a 50% reduction of AdoHcyase activity in intact normal erythrocytes. More precise studies of inactivation kinetics in intact erythrocytes were not attempted because of the inability to control the phosphorolytic cleavage of inosine to hypoxanthine and ribose-l-PO4 by PNP. The equilibrium for the PNP reaction is known to favor nucleoside formation (19) , but in the intact cell the reaction is "pulled" in the direction of cleavage by removal of hypoxanthine, suggesting an explanation for the 50-60% (12) deficiency of AdoHcyase in the erythrocytes of HGPRT-deficient patients: higher steady-state concentrations of guanine or hypoxanthine (particularly the latter in the allopurinol-treated pa- Purified placental AdoHcyase (0.9 ug) was incubated with the indicated concentrations of inosine in 25 mM potassium phosphate, pH 7.0, 1 mM dithiothreitol, and 1 mM disodium EDTA. At the indicated times 0.005-ml aliquots were transferred to AdoHcyase assay mixtures, and capacity to synthesize AdoHcy was measured as described in Fig. 1.  (B) Reciprocal plot of first-order rate constants for inactivation (kinactivation) calculated from (A) vs. inosine concentration. K, (18) is an index of the equilibrium constant for the enzymeinosine complex from which inactivation proceeds. The maximal rate of inactivation at saturating inosine, estimated from the y intercept, is -0.16/min for the experiment shown. Purified placental AdoHcyase was dialyzed as described in Fig. 1, and 1.4 ,ug was incubated at 37°C with the indicated purines, 250 ,mM, in preincubation mixtures (0.05 ml) containing 25 mM potassium phosphate, pH 7.0, 1 mM dithiothreitol, and 1 mM Na2 EDTA. At various times aliquots were removed as described in Fig. 1 for measuring tient) could increase the steady-state concentration of intracellular inosine and cause a slow but progressive inactivation of AdoHcyase activity in long-lived erythrocytes. We have tested this hypothesis in an experiment employing cultured HGPRT-deficient human lymphoblastoid cells (Table II) . Hypoxanthine alone had little if any effect on intracellular AdoHcyase activity, but clearly potentiated the effect of inosine. The increase in AdoHcyase activity in the inosinetreated cultures between 6 and 24 h of incubation probably results from synthesis of new enzyme, which cannot occur in mature erythrocytes.
DISCUSSION
We have confirmed the finding of a significant (80-90%) decrease in erythrocyte AdoHcyase in PNP deficiency reported by Kaminska and Fox (12) , and we are able to offer a reasonable explanation for its occurrence. ,uM for deoxyadenosine and 24 uM for adenine arabinoside [9] ), the concentration of plasma inosine in PNP-deficient patients has been reported in the 40-100 ,uM range (20, 21) , whereas deoxyadenosine in the plasma of ADA-deficient children is usually <2 AM (10, 22) . Slow, irreversible inactivation by inosine in long-lived erythrocytes, which are incapable ofnew enzyme synthesis, seems the most likely explanation for the observed deficiency of AdoHcyase. The ability of hypoxanthine to displace the equilibrium of the PNP reaction toward inosine formation can explain its potentiation of the effect of inosine on AdoHcyase in HGPRT-deficient human lymphoblasts (Table II) , and probably accounts for the lower erythrocyte AdoHcyase deficiency that has been found in Lesch-Nyhan patients.
Could the observed deficiencies of AdoHcyase contribute to the clinical manifestations of HGPRT or PNP deficiency? Abnormalities in neurotransmitter methylation might conceivably play some role in producing the motor disturbance or self-mutilation that occurs in the Lesch-Nyhan syndrome. However, since more extensive AdoHcyase inactivation in both ADA and PNP deficiency does not result in any neurologic disease, this seems unlikely. More consideration needs to be given to the possibility that interaction of intracellular AdoHcyase with inosine contributes to the lymphopenia and defect in cell-mediated immunity in PNP deficiency. Both lymphopenia and AdoHcyase inactivation do occur in ADA deficiency, and selec-In Vivo Inactivation of S-Adenosylhomocysteine Hydrolase by Inosine tive lymphopenia has also recently been reported to occur in Ara-A-treated patients (23) , in whose blood cells AdoHcyase inactivation has been observed (24, 25, and our unpublished studies). However, inosine is not likely to produce as complete inactivation of AdoHcyase in cells capable of protein synthesis as either deoxyadenosine or Ara-A.
We have shown that inosine, unlike deoxyadenosine or Ara-A, can also act as a nucleoside substrate in the formation of a thioether bond with L-homocysteine. Though the Km for inosine is nearly four orders of magnitude higher than that of adenosine, there has been a report of the detection of trace amounts of InoHcy in mouse lymphoblasts exposed to 150 ,uM inosine (26) . Although some accumulation ofInoHcy in cells ofPNPdeficient patients may occur, InoHcy is probably much less effective than AdoHcy as an inhibitor of methylation reactions. Inosine is virtually nontoxic to PNP-deficient mouse lymphoblasts (27) , in marked contrast to the AdoHcy-mediated toxicity of adenosine to ADAinhibited mouse (7) and human (8) lymphoblasts. L-Homocysteine greatly potentiates adenosine toxicity by augmenting AdoHcy synthesis catalyzed by AdoHcyase. In preliminary experiments we have found that 1 mM inosine did not inhibit growth of WI-L2 lymphoblasts, alone or in the presence of 1 mM Lhomocysteine.
Although additional studies in PNP-deficient lymphoid cells would be uiseful, it presently seems unlikely that inosine produces sufficient AdoHcyase inactivation to cause significant accumulation of AdoHcy, or that its conversion to InoHcy by AdoHcyase is sufficiently toxic to contribute to the selective T cell defect in PNP deficiency. The more severe defects in both T and B cell development in ADA deficiency may, however, be attributable in part to the far more potent interactions of both adenosine and deoxyadenosine with AdoHcyase, a hypothesis under investigation.
